AIRLINK 69.20 Decreased By ▼ -3.86 (-5.28%)
BOP 4.89 Decreased By ▼ -0.20 (-3.93%)
CNERGY 4.23 Decreased By ▼ -0.14 (-3.2%)
DFML 30.70 Decreased By ▼ -1.75 (-5.39%)
DGKC 76.75 Increased By ▲ 1.26 (1.67%)
FCCL 19.91 Increased By ▲ 0.39 (2%)
FFBL 35.00 Decreased By ▼ -1.15 (-3.18%)
FFL 9.19 Decreased By ▼ -0.03 (-0.33%)
GGL 9.84 Decreased By ▼ -0.01 (-0.1%)
HBL 112.80 Decreased By ▼ -3.90 (-3.34%)
HUBC 133.00 Increased By ▲ 0.31 (0.23%)
HUMNL 6.95 Decreased By ▼ -0.15 (-2.11%)
KEL 4.17 Decreased By ▼ -0.24 (-5.44%)
KOSM 4.27 Decreased By ▼ -0.13 (-2.95%)
MLCF 36.36 Increased By ▲ 0.16 (0.44%)
OGDC 132.10 Decreased By ▼ -1.40 (-1.05%)
PAEL 22.29 Decreased By ▼ -0.31 (-1.37%)
PIAA 24.18 Decreased By ▼ -1.83 (-7.04%)
PIBTL 6.44 Decreased By ▼ -0.11 (-1.68%)
PPL 115.78 Increased By ▲ 0.47 (0.41%)
PRL 25.80 Decreased By ▼ -0.83 (-3.12%)
PTC 13.05 Decreased By ▼ -1.05 (-7.45%)
SEARL 51.88 Decreased By ▼ -1.57 (-2.94%)
SNGP 67.60 Increased By ▲ 0.35 (0.52%)
SSGC 10.55 Decreased By ▼ -0.15 (-1.4%)
TELE 8.26 Decreased By ▼ -0.16 (-1.9%)
TPLP 10.75 No Change ▼ 0.00 (0%)
TRG 59.21 Decreased By ▼ -4.66 (-7.3%)
UNITY 25.15 Increased By ▲ 0.03 (0.12%)
WTL 1.27 No Change ▼ 0.00 (0%)
BR100 7,391 Decreased By -70.2 (-0.94%)
BR30 23,890 Decreased By -281.6 (-1.16%)
KSE100 70,638 Decreased By -464.6 (-0.65%)
KSE30 23,239 Decreased By -155.5 (-0.66%)
World

First known US cases of potent South African COVID-19 variant found in South Carolina

  • The U.S. Centers for Disease Control and Prevention (CDC) has predicted the UK variant could become the dominant strain in the United States by March.
Published January 29, 2021

A potent coronavirus variant originating in South Africa and found to be partly resistant to current vaccines and antibody treatments has been detected for the first time in the United States in two South Carolina patients, health officials said on Thursday.

Medical experts said arrival of the so-called South African variant presented an alarming new challenge in efforts to contain a raging pandemic that has claimed at least 430,000 American lives in 11 months, as authorities struggle to launch the largest mass-vaccination campaign in U.S. history.

All viruses mutate frequently, and scientists have identified several variants of the novel coronavirus found to be more transmissible than the original strain.

But the presence of the South African variant, which has shown no evidence of causing more severe disease, is nonetheless especially concerning because several laboratory studies have found that it reduces vaccine and antibody therapy efficacy.

Confirmation of two patients with that variant in South Carolina came days after the Minnesota Department of Health identified the first known U.S. case of another highly contagious strain that originated in Brazil.

Yet a third form of the virus from the UK that is more infectious, and associated with higher mortality, made its first U.S. appearance last month in Colorado and has since been detected in at least 28 states.

The flurry of variants taken together “have really changed the entire picture of the COVID-19 pandemic,” Dr. Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy, said in an MSNBC interview. “We’re now in by far the most dangerous period of the pandemic.”

The U.S. Centers for Disease Control and Prevention (CDC) has predicted the UK variant could become the dominant strain in the United States by March.

Dr. Anthony Fauci, the leading U.S. infectious disease specialist, told MSNBC all the new variants were worrisome, but “the one that is of greater concern and that really could be problematic is the mutant that is now dominant in South Africa.”

So far, the two-dose vaccines made by Moderna Inc and Pfizer Inc with BioNTech 22UAy.DE appear protective against the South African variant, despite a weaker immune response.

The companies said this week they were considering making new versions of their shots just in case. Moderna also plans to test giving a third shot of its vaccine to bolster antibody levels.

Comments

Comments are closed.